Products
The company’s limb salvage and reconstruction solutions focus on reducing complexity and addressing clinical challenges involving soft tissue failures and aseptic loosening through a personalized approach.
onkossurgical.comCrawled Oct 16, 2026
The company’s limb salvage and reconstruction solutions focus on reducing complexity and addressing clinical challenges involving soft tissue failures and aseptic loosening through a personalized approach.
The team works in musculoskeletal oncology and complex orthopaedics.
The Onkos leadership team works with surgeons to identify solutions for patients with these conditions and understand surgeons’ clinical challenges.
The company believes people with cancer and other complex orthopaedic conditions requiring surgery deserve tailored solutions and an organization that champions their cause.
The company welcomes contact from hospitals, surgeons, staff members, distributors, and community members.
The First FDA Granted Antibacterial Coating Technology shown to protect orthpaedic implants from bacteria at the time of surgery prior to implantation.
Onkos Surgical’s privacy policy describes how it processes information collected through its website, social media platforms, contact with the company, and product purchases, as well as the choices people have regarding their information.
Onkos Surgical completes its 1,000th case using **My3D patient-specific pelvic implants**, combining 3D anatomic modeling and virtual surgical planning for complex pelvic reconstruction. The milestone highlights growing adoption of its FDA-cleared, personalized implant solutions in musculoskeletal oncology and orthopedic surgery. The technology tailors implants to individual patient anatomy, improving precision in surgical procedures.
Onkos Surgical completes its **500th surgical case** using **NanoCept antibacterial technology** on the **ELEOS Limb Salvage System**, marking expanded adoption in musculoskeletal oncology procedures. The implant technology, authorized via **De Novo clearance in 2024**, integrates into complex orthopedic interventions to address infection risks. The milestone underscores growing clinical use of Onkos Surgical’s specialized solutions for limb salvage and oncology-related orthopedic challenges.
Onkos Surgical completes the first human surgeries using its NanoCept antibacterial coating on orthopaedic implants. The technology aims to reduce bacterial contamination during complex orthopaedic procedures. NanoCept is applied directly to implants to enhance infection prevention in surgical settings.
Onkos Surgical receives FDA 510(k) clearance for its **BioGrip Modular Porous Collars**, a first-of-its-kind solution targeting implant loosening in orthopedic oncology and complex revision surgeries. The device integrates into the **ELEOS Limb Salvage System** and features a **3D-printed porous design** to promote bone ingrowth. It addresses critical challenges in musculoskeletal oncology and limb salvage procedures.
Onkos Surgical introduces the **ELEOS Proximal Tibia implant**, featuring **BioGrip technology** for enhanced fixation in musculoskeletal oncology and complex orthopedic reconstructions. The product expands the company’s portfolio of personalized orthopedic solutions, addressing bone tumor resection and limb-sparing procedures. BioGrip technology aims to improve implant stability and integration for patients requiring proximal tibia replacements.